Enterprise Value
1.553B
Cash
1.768B
Avg Qtr Burn
-85.75M
Short % of Float
17.30%
Insider Ownership
1.38%
Institutional Own.
67.47%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CASGEVY™ (Exagamglogene autotemcel) (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) Details Beta thalessemia Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
CASGEVY™ (Exagamglogene autotemcel) (CTX001) (autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy) (Exa-cel) Details Sickle cell disease Big Mover™ Suspected Mover™ Susp. Mover™ | PDUFA Approval decision | |
CTX110 (CD19) Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies | Phase 2 Data readout | |
VCTX211 Details Type 1 diabetes | Phase 1/2 Data readout | |
Phase 1/2 Update | ||
Phase 1/2 Update | ||
CTX112 (CD19) Details CD19+ malignancies, Blood cancer, Cancer, B-cell malignancies | Phase 1 Data readout | |
VCTX210 Details Type 1 diabetes | Phase 1 Data readout | |
CTX131 (CD70) Details Cancer, Solid tumor/s | Phase 1 Update | |
CTX130 (CD70) Details Blood cancer, Cancer, T-cell lymphoma | Phase 1 Update | |
CTX120 (BCMA) Details Multiple myeloma, Blood cancer, Cancer | Failed Discontinued |